Faeth Therapeutics (FTH) analyst forecast and price target
Analyst forecast
Consensus of 14 analyst ratings
Based on 9 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Initiated Coverage | Buy | $70.00 | Sep 16, 2026 |
| LUCID CAPITAL MARKETS | Initiated Coverage | Buy | $59.00 | Sep 14, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Sep 9, 2026 |
| Needham | Initiated Coverage | Buy | $56.00 | Aug 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60.00 | Aug 11, 2026 |
| Jones Trading | Initiated Coverage | Buy | $55.00 | Aug 4, 2026 |
| Raymond James | Initiated Coverage | Outperform | $56.00 | Jul 31, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $60.00 | Jul 28, 2026 |
| Citizens | Initiated Coverage | Market Outperform | $51.00 | Jul 20, 2026 |
| BTIG | Maintained | Buy | $55.00 | Jul 16, 2026 |
| Baird | Initiated Coverage | Outperform | $57.00 | Jun 26, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $60.00 | Jun 22, 2026 |
| BTIG | Maintained | Buy | $55.00 | Jun 15, 2026 |
| BTIG | Initiated Coverage | Buy | $55.00 | Jun 11, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | May 29, 2026 |
| LUCID CAPITAL MARKETS | Initiated Coverage | Buy | $50.00 | May 28, 2026 |
| Citigroup | Initiated Coverage | Buy | $55.00 | May 22, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Oct 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $30.00 from $5.00 | Aug 5, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $5.00 | Jun 2, 2025 |
Frequently asked questions
What is the price target for FTH stock?
The average 12-month analyst price target for Faeth Therapeutics (FTH) is $58.00, with a high estimate of $70.00 and a low of $51.00, across 9 analysts.
Is FTH a buy, sell, or hold?
Analysts covering Faeth Therapeutics currently average a Buy rating: 14 buy, 0 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for FTH?
The average price target of $58.00 implies 189.28% upside from the last price of $20.05.
What is the latest analyst rating on FTH?
On Sep 16, 2026, Guggenheim initiated coverage of Faeth Therapeutics at Buy with a price target of $70.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.